A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Protocol: ECOG – EA8192 SCHEMA EA8192 Please Note: Below is partial eligibility, for full eligibility requirements, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: Patient must be ≥18 years of age. Patient must have a diagnosis of high grade upper tract urothelial carcinoma proven by biopsy […]
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Maintenance Avelumab After First Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
Protocol: Alliance – A032001 SCHEMA A032001 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Histologically or cytologically-confirmed diagnosis of advanced or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra (transitional cell and mixed transitional/non-transitional […]
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response Gene Alterations
Protocol: Alliance A031701 SCHEMA A031701 Please Note: Below is a partial list of eligibility, please contact GHCI Research Department for full eligibility requirements. Thank you! Eligibility: Histologically confirmed muscle-invasive urothelial carcinoma of the bladder. Urothelial carcinoma invading into the prostatic stroma with no histologic muscle invasion is allowed, provided the extent of disease is confirmed […]
Phase II Trial of Intravesical Gemcitabine and Pembrolizumab in Treatment of Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer
PROTOCOL: Alliance-A031803 SCHEMA A031803 Please Note: Below is partial list of eligibility, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 for full eligibility requirements. Thank you! ELIGIBILITY: High grade Ta, T1 or CIS urothelial carcinoma. Accrual of patients with Ta or T1 disease may be closed to ensure adequate patients […]